(MENAFN- Investor Brand Network)
SIGA Technologies Inc. (NASDAQ:SIGA) traded at a new 52-week high today of $23.87. So far today approximately 2.3 million shares have been exchanged, as compared to an average 30-day volume of 14.5 million shares.
Over the past year, SIGA Technologies Inc. has traded in a range of $5.84 to $23.87 and is now at $22.94, 293% above that low.
SIGA Technologies Inc. (NASDAQ:SIGA) is currently priced 20.7% above its average consensus analyst price target of $18.18.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's lead product is TPOXX, an orally administered antiviral drug for the treatment of human smallpox disease caused by the variola virus. Its products target orthopoxvirus infections including smallpox.
Receive IBN Spotlights –“Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights , please visit
About IBN (InvestorBrandNetwork)
IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years . Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series . With a proven track record serving 500+ client partners , IBN is the key to a more effective market communication campaign and the NEW normal.
For more information on IBN, please visit
Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.